Success Story: From Molecular Biology Research to NIW Approval for a Precision Medicine Researcher
Client’s Testimonial:
"Thank you very much again for your help in putting together my I-140 package. I am very pleased to have the outright approval granted yesterday without an RFE!”
On September 8th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Senior Research Associate in the Field of Molecular Biology (Approval Notice).
General Field: Molecular Biology
Position at the Time of Case Filing: Senior Research Associate
Country of Origin: Philippines
State of Residence at the Time of Filing: Ohio
Approval Notice Date: September 8th, 2026
Processing Time: 14 months, 6 days (Premium Processing Upgrade Requested)
Case Summary:
As scientific research increasingly supports advances in healthcare and biotechnology, researchers face the important challenge of translating complex scientific findings into practical applications that can benefit society. The client, a molecular biology researcher with an M.S. in molecular biology and biotechnology, has developed a research record addressing broader scientific and biomedical needs. We represented the client in an I-140 National Interest Waiver (NIW) petition, which was approved without a Request for Evidence (RFE).
Building More Targeted Approaches for Genetic Disease and Cancer Research
The client’s proposed endeavor focuses on advancing biomedical research and developing innovative molecular, cellular, and genomic approaches to better understand and address significant health conditions.
The petition emphasized the broader importance of the client’s work in supporting scientific progress, improving medical knowledge, and contributing to the development of more effective treatments and healthcare solutions. The client currently works as a senior research associate at a U.S.-based biomedical research institution, where the client conducts research involving advanced biological and medical research methods. The petition connected this ongoing work to broader U.S. interests in scientific innovation, healthcare advancement, disease research, and improved patient outcomes.
A Record of Research That Others Have Used
To demonstrate that the client was well positioned to continue this endeavor, we presented several complementary indicators of research productivity and influence:
- 4 peer-reviewed journal articles, including 3 first-authored or co-first-authored articles
- 20 conference abstracts, including 8 first-authored abstracts
- 1 first-authored preprint and 1 patent application
- 63 citations to the client’s published research
The petition did not rely on these figures as accomplishments that spoke for themselves. Instead, we showed how independent researchers had incorporated the client’s findings and methods into subsequent studies involving broader areas of biomedical and life sciences research. One publication also ranked among the top 20% most-cited Biology & Biochemistry articles for its publication year. This comparative evidence helped demonstrate that the client’s work had attracted meaningful attention within the field.
We further documented research support from major health and defense-related funding sources, including the National Institutes of Health (NIH). This funding provided another objective indicator of interest in research areas connected to the client’s broader work. Taken together, the client’s scholarly output, citation record, independently documented use of the research, scientific advisory committee service, funding support, technical background, and continuing research plans demonstrated a sustained trajectory rather than isolated achievements.
Expert Support for Continued Research
The petition was further supported by 4 recommendation letters from experts familiar with the client’s accomplishments. The letters discussed the client’s research record, specialized expertise, and ability to continue advancing work relevant to molecular biology, genetic disease research, cancer biology, and precision medicine. One expert noted:
"Ensuring that her work continues is therefore critical to maintaining the U.S.’ leadership in advanced biomedical research and innovation."
The approval of the client’s I-140 NIW petition represents an important milestone in this continuing research journey. The case was grounded not simply in numerical credentials, but in evidence showing how the client’s work has gained independent recognition and can continue contributing to molecular biology, gene therapy, cancer research, and precision medicine in the United States.